Literature DB >> 18628657

Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial.

Christopher D Gardner1, Ruth E Taylor-Piliae, Alexandre Kiazand, Joel Nicholus, Alison J Rigby, John W Farquhar.   

Abstract

PURPOSE: Medical therapies for treatment of peripheral artery disease (PAD) are limited. Ginkgo biloba has been reported to increase maximal and pain-free walking distance among patients with PAD; however, the evidence is inconsistent. The objective of this study was to compare the effects of 300 mg/d of Ginkgo biloba (EGb 761) versus placebo on treadmill walking time and related cardiovascular measures among patients with PAD.
METHODS: A double-blind, placebo-controlled, parallel design trial with a 4-month duration was used. Participants were 62 adults, aged 70 +/- 8 years (mean +/- SD), with claudication symptoms of PAD. The primary study outcomes were maximal and pain-free walking time on a treadmill. Secondary outcomes included flow-mediated vasodilation, a measure of antioxidant status as assessed by determining antibody levels to epitopes of oxidized low-density lipoprotein, and questionnaires addressing walking impairment and quality of life.
RESULTS: Maximal treadmill walking time increased by 20 +/- 80 and 91 +/- 242 seconds in the placebo and the EGb 761 groups, respectively (P = .12). Pain-free walking time increased by 15 +/- 31 and 21 +/- 43 seconds, respectively (P = .28). No significant differences were detected between groups for any of the secondary outcomes.
CONCLUSIONS: In older adults with PAD, Ginkgo biloba produced a modest but insignificant increase in maximal treadmill walking time and flow-mediated vasodilation. These data do not support the use of Ginkgo biloba as an effective therapy for PAD, although a longer duration of use should be considered in any future trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628657      PMCID: PMC2748261          DOI: 10.1097/01.HCR.0000327184.51992.b8

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  35 in total

1.  Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.

Authors:  M H Pittler; E Ernst
Journal:  Am J Med       Date:  2000-03       Impact factor: 4.965

2.  Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation.

Authors:  S Akiba; T Kawauchi; T Oka; T Hashizume; T Sato
Journal:  Biochem Mol Biol Int       Date:  1998-12

3.  World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

4.  Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.

Authors:  Jessica Rodenburg; Maud N Vissers; Albert Wiegman; Elizabeth R Miller; Paul M Ridker; Joseph L Witztum; John J P Kastelein; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2006-04-17       Impact factor: 24.094

Review 5.  The US experience with cilostazol in treating intermittent claudication.

Authors:  William R Hiatt
Journal:  Atheroscler Suppl       Date:  2005-11-04       Impact factor: 3.235

6.  Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist.

Authors:  P Braquet
Journal:  Am J Gastroenterol       Date:  1993-12       Impact factor: 10.864

7.  Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older adults with intermittent claudication.

Authors:  Anna Maria Izquierdo-Porrera; Andrew W Gardner; Douglas D Bradham; Polly S Montgomery; John D Sorkin; Claudia C Powell; Leslie I Katzel
Journal:  J Vasc Surg       Date:  2005-04       Impact factor: 4.268

8.  Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease.

Authors:  M M McDermott; K Liu; J M Guralnik; G J Martin; M H Criqui; P Greenland
Journal:  J Vasc Surg       Date:  1998-12       Impact factor: 4.268

9.  Exercise training improves functional status in patients with peripheral arterial disease.

Authors:  J G Regensteiner; J F Steiner; W R Hiatt
Journal:  J Vasc Surg       Date:  1996-01       Impact factor: 4.268

10.  Peripheral arterial disease: identification and implications.

Authors:  Emile R Mohler
Journal:  Arch Intern Med       Date:  2003-10-27
View more
  9 in total

1.  The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects.

Authors:  Ho-Sook Kim; Ga-Young Kim; Chang-Woo Yeo; Minkyung Oh; Jong-Lyul Ghim; Ji-Hong Shon; Eun-Young Kim; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  Dietary supplement with a combination of Rhodiola crenulata and Ginkgo biloba enhances the endurance performance in healthy volunteers.

Authors:  Zhang-jin Zhang; Yao Tong; Jun Zou; Pei-jie Chen; Ding-hai Yu
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

Review 3.  Ginkgo biloba for intermittent claudication.

Authors:  Saskia P A Nicolaï; Lotte M Kruidenier; Bianca L W Bendermacher; Martin H Prins; Rutger A Stokmans; Pieter P H L Broos; Joep A W Teijink
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

4.  The tandem of full spin analysis and qHNMR for the quality control of botanicals exemplified with Ginkgo biloba.

Authors:  José G Napolitano; Tanja Gödecke; María F Rodríguez-Brasco; Birgit U Jaki; Shao-Nong Chen; David C Lankin; Guido F Pauli
Journal:  J Nat Prod       Date:  2012-02-14       Impact factor: 4.050

5.  Does Ginkgo biloba reduce the risk of cardiovascular events?

Authors:  Lewis H Kuller; Diane G Ives; Annette L Fitzpatrick; Michelle C Carlson; Carla Mercado; Oscar L Lopez; Gregory L Burke; Curt D Furberg; Steven T DeKosky
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-11-24

Review 6.  Medical management for chronic atherosclerotic peripheral arterial disease.

Authors:  Farzana Nawaz Ali; Teresa L Carman
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

Review 7.  Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.

Authors:  Abdullah Shaito; Duong Thi Bich Thuan; Hoa Thi Phu; Thi Hieu Dung Nguyen; Hiba Hasan; Sarah Halabi; Samar Abdelhady; Gheyath K Nasrallah; Ali H Eid; Gianfranco Pintus
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

Review 8.  Physical activity in the prevention of peripheral artery disease in the elderly.

Authors:  Gabriele G Schiattarella; Cinzia Perrino; Fabio Magliulo; Andreina Carbone; Antonio G Bruno; Michele De Paulis; Antonio Sorropago; Roberto V Corrado; Roberta Bottino; Giovanni Menafra; Raffaele Abete; Evelina Toscano; Giuseppe Giugliano; Bruno Trimarco; Giovanni Esposito
Journal:  Front Physiol       Date:  2014-03-03       Impact factor: 4.566

Review 9.  Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders.

Authors:  Kevin M Nash; Zahoor A Shah
Journal:  Integr Med Insights       Date:  2015-11-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.